Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer

Core Insights - Kalm Therapeutics has appointed Dr. Tomoko Maeda-Chubachi as Chief Medical Officer to oversee the design and submission of their Phase 1b/2a clinical trial protocol to the FDA [1][4] Company Overview - Kalm Therapeutics, founded in 2024, is a pre-clinical drug development company focused on a medicated, controlled-release patch for the non-steroidal treatment of mild to moderate atopic dermatitis and psoriasis [4] Leadership Experience - Dr. Maeda-Chubachi has extensive experience in dermatology drug development, having worked with Pfizer, Eli Lilly, and GSK, where she led the Phase II clinical trial of the eczema/psoriasis topical cream Vtama, which was acquired by Dermavant for $250 million [3] - Most recently, she served as Chief Medical Officer at Pelthos Therapeutics, where she led the approval of Zelsuvmi for molluscum contagiosum [3] Industry Context - Eczema remains a complex disease requiring diverse therapeutic options, and Dr. Maeda-Chubachi expressed excitement about developing the Kalm Patch as a new management solution for eczema [2]